In AML, there are some ongoing clinical trials to evaluate the efficacy and safety of Hu5F9G4, which is a monoclonal anti-CD47 antibody for R/R AML patients (NCT02678338, NCT03248479). The gene discussed is CD47; the disease is acute myeloid leukemia.